IQVIA Holdings Inc. (IQV)

NYSE: IQV · IEX Real-Time Price · USD
217.73
-2.82 (-1.28%)
Dec 2, 2022 4:03 PM EST - Market closed
-1.28%
Market Cap 40.96B
Revenue (ttm) 14.31B
Net Income (ttm) 1.18B
Shares Out 186.50M
EPS (ttm) 6.06
PE Ratio 35.93
Forward PE 19.12
Dividend n/a
Ex-Dividend Date n/a
Volume 864,231
Open 216.13
Previous Close 220.55
Day's Range 214.05 - 219.04
52-Week Range 165.75 - 285.61
Beta 1.38
Analysts Buy
Price Target 258.38 (+18.7%)
Earnings Date Oct 26, 2022

About IQV

IQVIA Holdings Inc. provides advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and dissemin... [Read more]

Industry Life Sciences Tools & Services
IPO Date May 9, 2013
CEO Ari Bousbib
Employees 85,000
Stock Exchange NYSE
Ticker Symbol IQV
Full Company Profile

Financial Performance

In 2021, IQVIA Holdings's revenue was $13.87 billion, an increase of 22.14% compared to the previous year's $11.36 billion. Earnings were $966.00 million, an increase of 246.24%.

Financial Statements

Analyst Forecast

According to 26 analysts, the average rating for IQV stock is "Buy." The 12-month stock price forecast is 258.38, which is an increase of 18.67% from the latest price.

Price Target
$258.38
(18.67% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Why Is IQVIA (IQV) Up 8.6% Since Last Earnings Report?

IQVIA (IQV) reported earnings 30 days ago. What's next for the stock?

1 week ago - Zacks Investment Research

Coeptis Therapeutics Engages IQVIA to Support SNAP-CAR Development Program

Coeptis to collaborate with IQVIA, a global contract research organization, to identify target indications and initiate IND-enabling activities for SNAP-CAR WEXFORD, Pa. , Nov. 22, 2022 /PRNewswire/ -- ...

Other symbols: COEP
1 week ago - PRNewsWire

3 Technology Services Stocks to Watch From a Promising Industry

The Zacks Technology Services industry seeks to benefit from the increased digitization and dependency on technology and the growing adoption of the multi-cloud model. IQV, MTTR and TSP are well-positio...

Other symbols: MTTRTSP
3 weeks ago - Zacks Investment Research

IQVIA (IQV) Q3 Earnings and Revenues Beat Mark, Rise Y/Y

IQVIA (IQV) third-quarter 2022 earnings and revenues surge year over year.

1 month ago - Zacks Investment Research

IQVIA Holdings (IQV) Q3 Earnings and Revenues Top Estimates

IQVIA (IQV) delivered earnings and revenue surprises of 3.77% and 0.45%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

1 month ago - Zacks Investment Research

IQVIA Reports Third-Quarter 2022 Results

RESEARCH TRIANGLE PARK, N.C.

1 month ago - Business Wire

Biosimilars Are Revolutionizing Healthcare: Is This Industry Leader a Buy?

Biosimilars are bringing down prescription drug costs without sacrificing quality.

Other symbols: AMGNAZNJNJNVSREGN
1 month ago - The Motley Fool

IQVIA Holdings (IQV) Earnings Expected to Grow: Should You Buy?

IQVIA (IQV) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 month ago - Zacks Investment Research

Here's Why You Should Invest in IQVIA Holdings (IQV) Now

IQVIA (IQV) aims at market expansion through innovation and service improvement.

1 month ago - Zacks Investment Research

IQVIA (IQV) Loses 22.4% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

The heavy selling pressure might have exhausted for IQVIA (IQV) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revi...

1 month ago - Zacks Investment Research

IQV vs. CLBT: Which Stock Is the Better Value Option?

IQV vs. CLBT: Which Stock Is the Better Value Option?

Other symbols: CLBT
1 month ago - Zacks Investment Research

Why IQVIA Holdings (IQV) is a Top Value Stock for the Long-Term

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

1 month ago - Zacks Investment Research

Q² Solutions Launches Innovative Self-Collection Safety Lab Panel in Collaboration With Tasso

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Q² Solutions, a wholly owned subsidiary of IQVIA and a leading global clinical trial laboratory services organization, today announced the launch of the fi...

1 month ago - Business Wire

IQVIA to Announce Third-Quarter 2022 Results on October 26, 2022

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV) will announce its third-quarter 2022 financial results before the market opens on Wednesday, October 26, 2022. The...

2 months ago - Business Wire

IQVIA Decentralized Clinical Trial Program Achieves Independent GDPR Validation

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA (NYSE:IQV), a leading global provider of advanced analytics, technology solutions and contract services to the life sciences industry, today announce...

2 months ago - Business Wire

The 7 Best Growth Stocks to Buy in October

Amid fears of persistent inflation and economic slowdown, many growth names, especially those that aren't yet profitable, have fared poorly this year. However, growth stocks tend to outperform the broad...

Other symbols: CRWDFANGGFSMETASPOTV
2 months ago - InvestorPlace

Here's Why a Hold Strategy is Apt for IQVIA (IQV) Stock

IQVIA's (IQV) enormous treasure trove of information is a distinguishing asset.

2 months ago - Zacks Investment Research

Analysts Totally Blow It On 12 Gutsy Stock Recommendations

Wall Street analysts follow S&P 500 stocks more closely than almost anyone. But even they get it wrong sometimes, too.

2 months ago - Investors Business Daily

Here's who could benefit from Biden's biotech initiative, according to Oppenheimer's Jared Holz

Oppenheimer's Jared Holz on President Biden's cancer initiative and what it means for biotech in the U.S. With CNBC's Melissa Lee and the Fast Money traders, Tim Seymour, Courtney Garcia, Guy Adami and ...

Other symbols: AAMGNCTLTDHRREGNTMO
2 months ago - CNBC Television

New IQVIA Study Demonstrates Cost and Time Savings of Decentralized Trials

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA™ (NYSE:IQV), a leading global provider of advanced analytics, technology solutions and clinical research services to the life sciences industry, toda...

2 months ago - Business Wire

IQVIA CEO Ari Bousbib to Speak at Baird Global Healthcare Conference on September 14, 2022

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), announced today that Ari Bousbib, chairman and chief executive officer, will speak at the Baird 2022 Global Healt...

3 months ago - Business Wire

IQVIA CFO Ron Bruehlman to Speak at Morgan Stanley Annual Global Healthcare Conference on September 13, 2022

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), announced today that Ron Bruehlman, executive vice president and chief financial officer, will speak at the Morga...

3 months ago - Business Wire

IQVIA Wins Snowflake's “Marketplace Healthcare and Life Sciences Partner of the Year” Award

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA (NYSE:IQV), a leading global provider of advanced analytics, technology solutions and contract services to the life sciences industry, today announce...

3 months ago - Business Wire